Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H21NO.ClH |
Molecular Weight | 303.826 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC(C1CCCCN1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=KIFIYUHFHGSNHL-UHFFFAOYSA-N
InChI=1S/C18H21NO.ClH/c20-18(15-9-3-1-4-10-15,16-11-5-2-6-12-16)17-13-7-8-14-19-17;/h1-6,9-12,17,19-20H,7-8,13-14H2;1H
Pipradrol (Meratran) is a psychoactive agent and a central nervous system stimulant useful in the field of psychiatry. In vitro study has shown that pipradrol inhibits the reuptake of and stimulates the release of dopamine and norepinephrine. In these pharmacodynamic actions it is less potent than d-amphetamine. It was shown that pipradrol conditioned place preference (CPP) was blocked by selective D1 dopamine antagonist SCH23390 suggesting that a rewarding effect of pipradrol establishment of a CPP may involve activation of D1 dopamine receptors. Pipradrol was initially used as an adjunct in the dietary management of obesity as well as for the treatment of dementia. There have been a number of reports on the properties of pipradrol showing its favorable effects in the treatment of depression and fatigue status as well as a variety of other conditions including narcolepsy, spasmodic torticollis, schizophrenia and in geriatric practice. Pipradrol has a definite cerebral stimulating effect without affecting the blood pressure or respiration and has been used to counteract post-anasthetic and chlorpromazine depression in man. Structurally related to -phenylmethylamphetamine, a potent stimulant with a long half-life, pipradrol differs from amphetamine in that its action is more intense at higher centres, it lacks pressor activity, there is no post-excitement depression, and it does not depress the desire for food as occurs with amphetamine. The drug however is enhancing the existing pathologic behavior such as exacerbating pre-existing anxiety and is considered the drug of abuse. Meratran has certain indications and contraindications. Indications are schizophrenics without delusions having restriction of interest and activity and with depressant features, psycho-motor retardation and/or blocking of communication, long-term hospitalized schizophrenics with severe deterioration while contraindications are patients with delusions, anxiety, disturbed patients with cerebral arteriosclerosis. Pipradrol was made illegal in many countries in 1970s due to its abuse potential. It is classified under the Misuse of Drugs Act as a Class C substance. The combination of pipradrol with multivitamins and minerals marketed as Alertonic Elixir is used as adjunctive therapy in combating fatigue resulting from emotional or nutritional causes.
Originator
Sources: https://www.google.com/patents/US2624739
Curator's Comment: Pipradrol was developed in the 1950s
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ALERTONIC Elixir Approved UseAlertonic is recommended for patients with functional or psychogenic fatigue. This frequently occurs in the absence of organic disease, during convalesence, the post-partum period and following infections, especially those of viral origin. Fatigue may also be present due to a nutritional deficiency which may occur in patients with an inadequate food intake or incorrect eating habits, in geriatric patients who have lost interest in food or in patients with, or recovering from, a debilitating illness or other stressful situations. Alertonic is indicated as a dietary supplement in nutritional fatigue when such fatigue is caused by a deficiency of those vitamins, minerals and trace elements supplied by Alertonic. While Alertonic cannot be expected to influence the basic course of a disease state, it can be useful as adjunctive therapy in combating fatigue resulting from emotional or nutritional causes. Launch Date1975 |
Doses
Dose | Population | Adverse events |
---|---|---|
7.5 mg 1 times / day multiple, oral Studied dose Dose: 7.5 mg, 1 times / day Route: oral Route: multiple Dose: 7.5 mg, 1 times / day Sources: |
unhealthy, 42 years n = 47 Health Status: unhealthy Condition: mild depression Age Group: 42 years Sex: M+F Population Size: 47 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Drugs which stimulate affective behaviour. 3. Comparison of the effect of picrotoxin, pentylenetetrazol, bemigride, pipradrol, ectylurea, vanillic acid diethylamide and deanol. | 1960 Jul |
|
Recreational drugs, 3,4-Methylenedioxymethamphetamine(MDMA), 3,4-methylenedioxyamphetamine (MDA) and diphenylprolinol, inhibit neurite outgrowth in PC12 cells. | 2010 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://home.intekom.com/pharm/adcock/alerton.html
Alertonic Elixir (each 5 ml contains 0.67 mg pipradrol hydrochloride with vitamins and minerals) administred in adults 3 medicine measurefuls (15 ml), children over 15 years : 1 - 2 medicine measurefuls, children 4 - 15 years: 1 medicine measureful. To be taken three times daily 30 minutes before meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/474143
The inhibitory potencies of 27 compounds including pipradrol on the accumulation of 3H-dopamine (DA) in synaptosome-rich striatal homogenates of normal and reserpinized rats were determined.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m8867
Created by
admin on Fri Dec 15 16:56:12 GMT 2023 , Edited by admin on Fri Dec 15 16:56:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
F6E46VR9Y2
Created by
admin on Fri Dec 15 16:56:12 GMT 2023 , Edited by admin on Fri Dec 15 16:56:12 GMT 2023
|
PRIMARY | |||
|
SUB03864MIG
Created by
admin on Fri Dec 15 16:56:11 GMT 2023 , Edited by admin on Fri Dec 15 16:56:11 GMT 2023
|
PRIMARY | |||
|
100000085310
Created by
admin on Fri Dec 15 16:56:12 GMT 2023 , Edited by admin on Fri Dec 15 16:56:12 GMT 2023
|
PRIMARY | |||
|
66008
Created by
admin on Fri Dec 15 16:56:12 GMT 2023 , Edited by admin on Fri Dec 15 16:56:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110938
Created by
admin on Fri Dec 15 16:56:11 GMT 2023 , Edited by admin on Fri Dec 15 16:56:11 GMT 2023
|
PRIMARY | |||
|
71-78-3
Created by
admin on Fri Dec 15 16:56:11 GMT 2023 , Edited by admin on Fri Dec 15 16:56:11 GMT 2023
|
PRIMARY | |||
|
DTXSID50991292
Created by
admin on Fri Dec 15 16:56:12 GMT 2023 , Edited by admin on Fri Dec 15 16:56:12 GMT 2023
|
PRIMARY | |||
|
200-764-7
Created by
admin on Fri Dec 15 16:56:12 GMT 2023 , Edited by admin on Fri Dec 15 16:56:12 GMT 2023
|
PRIMARY | |||
|
DBSALT001777
Created by
admin on Fri Dec 15 16:56:11 GMT 2023 , Edited by admin on Fri Dec 15 16:56:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD